

## Predominance of *Chlamydia trachomatis* Serovars Associated with Urogenital Infections in Females in New Delhi, India

Vineeta Singh,<sup>1</sup> Sudha Salhan,<sup>2</sup> B. C. Das,<sup>3</sup> and A. Mittal<sup>1\*</sup>

Institute of Pathology-ICMR,<sup>1</sup> and Department of Obstetrics and Gynecology,<sup>2</sup> Safdarjang Hospital, New Delhi 110 029, and Institute of Cytology and Preventive Oncology-ICMR, Maulana Azad Medical College Campus, Bahadur Shah Zafar Marg, New Delhi 110 002,<sup>3</sup> India

Received 30 October 2002/Returned for modification 23 December 2002/Accepted 26 February 2003

**Screening for *Chlamydia trachomatis* was done for 280 endocervical swab samples by PCR specific for endogenous plasmid. Age dependency was seen in symptomatic patients, with a high chlamydial prevalence rate (28%) found in younger women. Genotyping by restriction fragment length polymorphism analysis of *omp1* PCR-positive samples showed serovars D, E, and F to be the most prevalent.**

*Chlamydia trachomatis* is a major cause of sexually transmitted disease (16). Serovars D to K are chiefly responsible for urogenital infections; of these serovars, E, F, and D account for up to 60 to 70% of these infections (1, 5, 14, 20). Epidemiological studies of *C. trachomatis* infections in sexual contacts have been few to date, which hampers the study of chlamydial transmission, its route of spread in a population, its virulence factors, and the associated risk factors of *C. trachomatis* infections (12, 19). Compared with immunotyping, the genotyping methods, particularly *omp1* are more sensitive and precise in revealing *C. trachomatis* variants within serovars as well as in potential recombinants among serovars (13, 15, 18). The present study was undertaken to understand the occurrence of *C. trachomatis* serovars in the genital tracts of infected women, which will help in devising an effective screening program for routine diagnosis of chlamydial infections, understanding the immunopathogenesis, and developing an effective chlamydial control program.

Reference *C. trachomatis* standard serovars were kindly provided by T. Ossewaarde (National Institute of Public Health and Environment Protection, Bilthoven, The Netherlands). Cervical swabs ( $n = 280$ ) were obtained from patients (17) attending the gynecology outpatient clinic for various gynecological reasons (abnormal vaginal discharge and pelvic pain) at Safdarjang Hospital, New Delhi, India. Chlamydial DNA was extracted from the clinical specimens by the alkali lysis method (2). The study protocol was approved by the committee responsible for the evaluation of work involving human subjects. Prior consent was obtained in all cases.

The clinical samples were first screened by a PCR specific for the human  $\beta$ -globin gene. The primers used for the human  $\beta$ -globin PCR were P1 (sense, 5' ACA CAA CTG TGT TCA CTA GC) and P2 (antisense, 5' GAA ACC CAA GAG TCT TCT CT). Samples positive in the  $\beta$ -globin PCR were used for *C. trachomatis* detection by using a plasmid PCR performed as described previously. The plasmid primers P3 (sense, 5'GAA CAA ATC GTA TCT CGG) and P4 (antisense, 5'GAA ACC

AAC TCT ACG TCG) generated a fragment of 517 bp in the *C. trachomatis*-positive samples. The *omp1* gene was amplified by primers selected from the published sequences of the *omp1* gene of *C. trachomatis* (L<sub>2</sub>) (21). The PCR mixture contained 25 pmol of each of the forward and reverse primers, 200  $\mu$ M concentrations of each of the deoxynucleoside triphosphates (dATP, dTTP, dGTP, and dCTP), 10 $\times$  PCR buffer (containing 10 mM Tris HCl [pH 8.3], 50 mM KCl, 2.5 mM MgCl<sub>2</sub>, 0.01% gelatin), and 0.1 U of *Taq* DNA polymerase (Gibco-BRL). PCR was performed in a thermocycler as follows: 5 min at 95°C; 40 cycles each consisting of denaturation at 94°C for 1 min, annealing at 60°C for 1 min, and extension at 72°C for 2 min; and a final elongation step of 10 min at 72°C. Restriction endonuclease digestion was performed with the restriction enzymes *AluI*, *CfoI*, *HinfI*, *DdeI*, and *EcoRI* (Promega, Madison, Wis.) on 5- $\mu$ l amounts of the amplified 871-bp PCR products by following the manufacturer's instructions.

All samples shown positive by the  $\beta$ -globin PCR assay were further screened by a plasmid PCR specific for the *C. trachomatis* endogenous plasmid. A clear age dependency was observed, showing a high prevalence rate among younger women. The overall prevalence rates of *C. trachomatis* in cervical swabs as determined by plasmid PCR were 28.5% in group I (age, 18 to 25 years), 7.6% in group II (age, 25 to 35 years), and 3.2% in group III (age, 35 to 45 years). *C. trachomatis*-positive swabs detected by plasmid PCR were further examined by *omp1* PCR for genotyping by restriction fragment length polymorphism. Purified PCR products were digested with *AluI* to differentiate serovars of *C. trachomatis* (Fig. 1). Serovars D and E showed fragments varying from 244 to 91 bp in size. Serovars B and D had a closely related pattern, except for the presence (serovar B) or absence (serovar D) of a 91-bp band in the digestion profile with *AluI*. The standard serovar F showed fragment sizes of 321 to 80 bp after digestion. Standard serovars L<sub>3</sub> and I, which are in the C complex, showed fragment of sizes 486 to 92 bp after digestion with *AluI*.

Serovars H, L<sub>3</sub>, and I were further distinguished by enzyme digestion with *EcoRI* and *DdeI*. With *EcoRI*, serovar I gave two bands, whereas with *DdeI*, it gave four bands varying between 323 to 80 bp in size. The clinical samples which were identified as having banding patterns matching that of serovar D after digestion with the *AluI* enzyme were further differen-

\* Corresponding author. Mailing address: Institute of Pathology-ICMR, Safdarjang Hospital Campus, Post Box No. 4909, New Delhi 110 029, India. Phone: 091-11-26198402. Fax: 091-011-6198401. E-mail: amittal\_jop@yahoo.com.




FIG. 1. *AluI* restriction endonuclease digestion of PCR products of *C. trachomatis*-positive clinical samples visualized by silver staining on polyacrylamide gel electrophoresis. Lanes: M, molecular size marker; 1, standard serovar D; 2, clinical sample showing banding pattern matching that of standard serovar D; 3, standard serovar E; 4, clinical sample showing banding pattern matching that of standard serovar E; 5, standard serovar F; 6, clinical sample showing banding pattern matching that of standard serovar F; 7, standard serovar I; 8, clinical sample showing banding pattern matching that of standard serovar I; 9, uncut amplicon.

tiated by digesting them with *CfoI* restriction enzyme. After analysis with the *CfoI* restriction enzyme, clinical samples were identified as serovar D, since they had an identical banding pattern as that of the standard serovar D. The restriction endonuclease sites for the various restriction enzymes are listed in Table 1.

*C. trachomatis* serovar D (48%) was found to be the most prevalent, followed by serovars E (34%), F (12%), and I (6%) in urogenital samples.

The present study demonstrated that the prevalence of symptomatic *C. trachomatis* infection is high in cervical swabs, as determined by a sensitive PCR assay, and is age dependent. These data are in agreement with earlier published reports showing high *C. trachomatis* rates (6, 10). The clinical samples could be discriminated by restriction endonuclease digestion with *AluI*. However, for a few clinical samples, digestion with *HinI*, *DdeI*, *CfoI*, and *EcoRI* was done, which further aided in discriminating among *C. trachomatis* serovars.

TABLE 1. Restriction endonuclease sites for different restriction enzymes

Serovar	Size (bp) of restriction endonuclease site for restriction enzyme:				
	<i>AluI</i>	<i>CfoI</i>	<i>DdeI</i>	<i>EcoRI</i>	<i>HinI</i>
A	486, 302, 138				
B	244, 225, 195, 91				
Ba	244, 204, 195, 91				
D	241, 225, 195	587, 408			
E	241, 225, 132, 102, 95				
F	321, 256, 207, 101, 80				
G	321, 207, 195, 107, 96, 80				
I	458, 302, 138		323, 285, 183	110	
J	435, 305, 138				540
L <sub>2</sub>	227, 225, 132, 102, 96				
L <sub>3</sub>	458, 305, 138			841, 131, 110	

In our study, serovar D (48%) was found to be the most prevalent serovar, followed by serovars E (34%), F (12%), and I (6%) in the urogenital samples. A similar distribution of *C. trachomatis* serovars has been reported earlier with tissue culture isolates (11). This pattern of serovar prevalence was found to be in accordance with the distribution of *C. trachomatis* serovars in other regions of the world (4, 7, 8, 9). We were not able to find other serovars J, H, K, or G of *C. trachomatis*, which have been reported by few workers (1, 3, 12). We did not observe any restriction endonuclease pattern different from the prototype or known variant strains in the 50 clinical samples examined. But this would have not been surprising, as others have found only a limited number of variants by serologic methods. In conclusion, *C. trachomatis* genotyping in women younger than age 30 years revealed that serovars D and E were more frequently found in symptomatic patients. The procedure we have used for cervical swabs by PCR restriction fragment length polymorphism analysis should enable basic serovar identification and provide a springboard for studies of variation.

This work was partly supported by the Department of Biotechnology, New Delhi, India.

REFERENCES

1. Banea, C. I., K. Kubota, T. M. Brown, P. H. Kilmarx, V. Bhullar, S. Yanparsain, P. Chaisilwattana, W. Siriwasin, and C. M. Black. 2001. Typing of *C. trachomatis* strains from urine samples by amplification and sequencing the major outer membrane protein gene (omp 1). *Sex. Transm. Infect.* **77**:419-422.
2. Birnboim, H. C., and J. Doly. 1979. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. *Nucleic Acid Res.* **7**:1513-1523.
3. Borrego, M. J., J. P. Gomes, J. F. Lefebvre, F. Eb, J. Orfila, and M. A. Cetry. 1997. Genotyping of Portuguese *Chlamydia trachomatis* urogenital isolates. *Genitourin. Med.* **73**:561-563.
4. Frost, E. H., S. Deslandes, S. Veilleux, and D. Bourgault-Ramoisy. 1991. Typing *C. trachomatis* by detection of RFLP in the gene encoding the MOMP. *J. Infect. Dis.* **163**:1103-1107.
5. Gaydos, C. A., L. Bobo, L. Welsh, E. W. Hook III, K. Viscidi, and T. C. Quinn. 1992. Genotyping of *Chlamydia trachomatis* by polymerase chain reaction and restriction endonuclease digestion. *Sex. Transm. Dis.* **19**:303-308.
6. Hammerschlag, M. R., N. H. Golden, K. Oh, M. Gelling, M. Sturdevant, B. R. Brown, Z. Aras, S. Neuhoff, W. Dumornay, and P. M. Rublin. 1993. Single dose of azithromycin for the treatment of genital chlamydial infection in adolescents. *J. Pediatr.* **122**:961-965.
7. Kuo, C. C., S. P. Wang, K. K. Holmes, and J. T. Grayston. 1983. Immunotypes of *Chlamydia trachomatis* isolates in Seattle, Washington. *Infect. Immun.* **41**:865-868.
8. Lan, J., C. J. L. M. Meijer, A. R. van den Hoek, J. M. Ossewaarde, J. M. M. Walboommers, and A. J. C. van den Brule. 1995. Genotyping of *C. trachomatis* serovars derived from heterosexual partners and a detailed genomic analysis of serovar F. *Genitourin. Med.* **71**:299-303.
9. Lan, J., I. Melgers, C. J. L. M. Meijer, J. M. M. Walboommers, R. Roosendaal, C. Burger, O. P. Bleker, and A. J. C. van den Brule. 1995. Prevalence and serovar distribution of asymptomatic cervical *Chlamydia trachomatis* infections as determined by highly sensitive PCR. *J. Clin. Microbiol.* **33**:3194-3197.
10. Mittal, A., S. Kapur, and S. Gupta. 1993. Chlamydial cervicitis: role of culture, enzyme immunoassay and Giemsa cytology in diagnosis. *Acta Pathol. Microbiol. Immun. Scand.* **101**:37-40.
11. Mittal, A. 1998. Serovar distribution of *C. trachomatis* isolates collected from the cervix: use of the polymerase chain reaction and restriction endonuclease digestion. *Br. J. Biomed. Sci.* **55**:179-183.
12. Moore, S. A., R. Moes, and I. Van Valkengoed. 1998. Genotyping of *Chlamydia trachomatis* in urine specimens will facilitate large epidemiological studies. *J. Clin. Microbiol.* **36**:3077-3078.
13. Ossewaarde, J. M., M. Rieffe, M. Rozenberg-Arska, P. M. Ossenkoppele, R. P. Nawrocki, and A. M. van Loon. 1992. Development and clinical evaluation of a polymerase chain reaction test for detection of *C. trachomatis*. *J. Clin. Microbiol.* **30**:2122-2128.
14. Rodriguez, P., B. de Barbeyrac, K. Persson, B. Dutlith, and C. Sebear. 1993. Evaluation of molecular typing for epidemiology study of *Chlamydia trachomatis* genital infections. *J. Clin. Microbiol.* **31**:2238-2240.

15. **Sayada, C., E. Denamur, J. Orfila, and J. Elion.** 1991. Rapid genotyping of the *C. trachomatis* major outer membrane protein by the PCR. *FEMS Microbiol. Lett.* **83**:73–78.
16. **Schachter, J.** 1999. Infection and epidemiology, p. 391–405. *In* R. S. Stephens (ed.), *Chlamydia: intracellular biology, pathogenesis, and immunity*. ASM Press, Washington, D.C.
17. **Singh, V., S. Rastogi, S. Garg, S. Kapur, A. Kumar, S. Salhan, and A. Mittal.** 2001. Polymerase chain reaction for detection of endocervical *C. trachomatis* infection in women attending a gynecology outpatient department in India. *Acta Cytol.* **46**:540–544.
18. **Stephens, R. S., E. A. Wagar, and G. K. Schoolnik.** 1988. High resolution mapping of serovar-specific and common antigenic determinants of the major outer membrane protein of *Chlamydia trachomatis*. *J. Exp. Med.* **167**:817–831.
19. **Viscidi, R. P., L. Bobo, E. W. Hook III, and T. C. Quinn.** 1993. Transmission of *C. trachomatis* among sex partners assessed by polymerase chain reaction. *J. Infect. Dis.* **168**:488–492.
20. **Wagenvoort, J. H. T., R. J. Suchland, and W. E. Stamm.** 1988. Serovar distribution of urogenital *C. trachomatis* strains in the Netherlands. *Genitourin. Med.* **64**:159–161.
21. **Yang, C. L., I. Maclean, and R. C. Brunham.** 1993. DNA sequence polymorphism of the *C. trachomatis* omp1 gene. *J. Infect. Dis.* **168**:1225–1230.